Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 4/20 | 1.00 |
| ▸ | SLC6A12 | P48065 | 3/20 | 0.41 |
| ▸ | SLC6A11 | P48066 | 3/20 | 0.41 |
| ▸ | SLC6A13 | Q9NSD5 | 3/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18503673 | 0.80 | HSD11B1 (0.67) | HSD11B1P2RX7CYP2C9EPHX2L3MBTL1 | |
| SCHEMBL18493703 | 0.80 | HSD11B1 (0.67) | HSD11B1P2RX7CYP2C9EPHX2L3MBTL1 | |
| SCHEMBL2793986 | 0.80 | HSD11B1 (0.67) | HSD11B1P2RX7CYP2C9EPHX2L3MBTL1 | |
| SCHEMBL2133238 | 0.78 | HSD11B1 (0.64) | HSD11B1P2RX7CYP2C9EPHX2L3MBTL1 | |
| SCHEMBL1997818 | 0.78 | HSD11B1 (0.63) | HSD11B1P2RX7CYP2C9EPHX2L3MBTL1 | |
| SCHEMBL8103086 | 0.78 | HSD11B1 (0.62) | HSD11B1SLC6A12SLC6A11SLC6A13CYP2C9 | |
| SCHEMBL1924918 | 0.76 | HSD11B1 (0.61) | HSD11B1P2RX7CYP2C9EPHX2L3MBTL1 | |
| SCHEMBL6159955 | 0.76 | HSD11B1 (0.61) | HSD11B1CYP2C9EPHX2L3MBTL1HSD17B10 | |
| SCHEMBL8098594 | 0.76 | HSD11B1 (0.61) | HSD11B1SLC6A12SLC6A11SLC6A13EPHX2 | |
| SCHEMBL1067170 | 0.76 | HSD11B1 (0.61) | HSD11B1SLC6A12SLC6A11SLC6A13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 133 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4063344-A1 | SALT OF 2-ADAMANTYL ACETIC ACID HAVING ANTI-VIRAL ACTIVITY, FORMULATIONS THEREOF AND USES THEREOF | Sciamannini, Umbro (IT) | 2022-09-28 | — | — | EP | claimed |
| JP-8198820-A | — | — | None | — | — | JP | disclosed |
| US-20260144743-A1 | COMPOUNDS | TMEM16A LIMITED (GB) | 2026-05-28 | — | — | US | disclosed |
| EP-4699655-A2 | COMPOUNDS | TMEM16A LIMITED (GB) | 2026-02-25 | — | — | EP | disclosed |
| US-12552770-B2 | Compounds for treating respiratory disease | TMEM16A LIMITED (GB) | 2026-02-17 | — | — | US | disclosed |
| US-12377105-B2 | Compounds | TMEM16A LIMITED (GB) | 2025-08-05 | — | — | US | disclosed |
| US-12274697-B2 | Compositions and methods for treating EZH2-mediated cancer | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2025-04-15 | — | — | US | disclosed |
| CN-119490451-A | Compounds as positive modulators of calcium activated chloride channels | TMEM16A有限公司 | 2025-02-21 | — | — | CN | disclosed |
| WO-2025034789-A1 | ARYLBENZOISOXAZOLE COMPOUNDS AS IP6K AND IPMK DEGRADERS AND METHODS OF USE THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2025-02-13 | — | — | WO | disclosed |
| US-20250000797-A1 | NANOMATERIALS | GUIDE THERAPEUTICS, LLC | 2025-01-02 | — | — | US | disclosed |
| EP-0568687-A1 | NOVEL AMYLIN ANTAGONIST PEPTIDES AND USES THEREFOR | AMYLIN PHARMACEUTICALS, INC. (US) | 1993-11-10 | — | — | EP | disclosed |
| WO-1993010147-A1 | NOVEL AMYLIN ANTAGONIST PEPTIDES AND USES THEREFOR | AMYLIN PHARMACEUTICALS, INC. (US) | 1993-05-27 | — | — | WO | disclosed |
| EP-0119359-B1 | ADAMANTYL CARBOXYLIC AND SULFONIC ACID CATALYZED PARAFFIN-OLEFIN ALKYLATION AND PARAFFIN ISOMERIZATION | EXXON RESEARCH AND ENGINEERING COMPANY (US) | 1987-06-10 | — | — | EP | disclosed |
| EP-0119359-A1 | Adamantyl carboxylic and sulfonic acid catalyzed paraffin-olefin alkylation and paraffin isomerization | EXXON RESEARCH AND ENGINEERING COMPANY (US) | 1984-09-26 | — | — | EP | disclosed |
| US-4426545-A | Adamantyl carboxylic and sulfonic acid catalyzed paraffin-olefin alkylation | EXXON RESEARCH AND ENGINEERING CO. (US) | 1984-01-17 | — | — | US | disclosed |
| US-4424387-A | STRONG ACID, BRANCHING | EXXON RESEARCH AND ENGINEERING CO. (US) | 1984-01-03 | — | — | US | disclosed |
| US-4349552-A | TREATMENT OF CANCER | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1982-09-14 | — | — | US | disclosed |
| EP-0010941-B1 | 5-FLUOROURACIL DERIVATIVES, PREPARATION THEREOF AND THEIR PHARMACEUTICAL COMPOSITIONS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1982-05-12 | — | — | EP | disclosed |
| EP-0010941-A1 | 5-Fluorouracil derivatives, preparation thereof and their pharmaceutical compositions | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1980-05-14 | — | — | EP | disclosed |
| US-4083973-A | ANABOLIC ACTIVITY, NANDROLONE | AKZONA INCORPORATED (US) | 1978-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260144743-A1 | COMPOUNDS | CACNA1E, TMEM109, CACNA1C | HSD11B1 908/4885SLC6A12 397/4885SLC6A11 81/4885 |
| US-12552770-B2 | Compounds for treating respiratory disease | TMEM109, SCN1A, SLC16A1 | HSD11B1 1125/4885SLC6A12 316/4885SLC6A11 101/4885 |
| US-12274697-B2 | Compositions and methods for treating EZH2-mediated cancer | EZH2, EZH1, EED | HSD11B1 1943/4885SLC6A12 4883/4885SLC6A11 4876/4885 |
| US-20250000797-A1 | NANOMATERIALS | POLRMT, PHOSPHO1, FABP1 | HSD11B1 4173/4885SLC6A12 3655/4885SLC6A11 3064/4885 |
| US-12377105-B2 | Compounds | CACNA1E, TMEM109, CACNA1A | HSD11B1 2457/4885SLC6A12 887/4885SLC6A11 174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.